Finasteride Compassionate Use and Expanded Access: How to Get It Cheaper in 2026

What Is Compassionate Use, and Does It Apply to Finasteride?

FDA compassionate use, formally called expanded access, is a pathway that lets patients use investigational or unapproved drugs outside a clinical trial when no comparable alternative exists. Because finasteride received FDA approval for androgenetic alopecia in 1992 and for BPH in 1992 as well, and because its patents expired in 2006, the drug is not investigational. That means the classical expanded access framework under 21 CFR Part 312 Subpart I does not apply to it in the way it applies to, say, an oncology biologic awaiting approval. [1]

The FDA defines expanded access as access to an investigational drug "for therapeutic purposes." [2] Finasteride is not investigational. Patients seeking it face an access problem driven by cost or prescription barriers, not regulatory status.

When Expanded Access Language Does Appear for Finasteride

The phrase "compassionate use" still appears in two real contexts for finasteride. First, some institutional review boards and hospital formulary committees use the term loosely to describe off-label prescribing in populations not covered by the label, such as adolescents with premature androgenetic alopecia or transgender women using it for androgen suppression. Second, certain international markets, including some EU member states, use national compassionate use programs for off-label finasteride in female-pattern hair loss because their local regulators have not approved the indication. [3]

Off-Label Prescribing Is Not the Same as Compassionate Use

Physicians in the United States may prescribe finasteride off-label without any special FDA permission. A 2022 review in the Journal of the American Academy of Dermatology confirmed that off-label finasteride 2.5 to 5 mg daily is used for female-pattern hair loss, with evidence from multiple randomized controlled trials. [4] Patients in that population access it through a standard prescription, not through any formal expanded access application.

The Real Access Problem: Cost and Prescription Barriers

Generic finasteride is one of the cheapest chronic medications available in the United States. Still, cost can be a barrier for uninsured patients, and prescription access can be a barrier for those without a primary care provider.

What Finasteride Actually Costs Without Insurance

Brand-name Propecia (1 mg, 30 tablets) lists at approximately $80, $110 per month at retail pharmacies in 2025. Generic finasteride 1 mg costs $10, $30 for 30 tablets at major chains. A GoodRx coupon at Costco Pharmacy or Walmart can bring a 90-tablet supply of 1 mg generic finasteride below $25 in many ZIP codes. [5]

The 5 mg generic tablet is often cheaper per milligram than the 1 mg tablet, a practice sometimes called "pill splitting." Splitting a 5 mg tablet yields four approximately 1.25 mg doses, and a 2019 pharmacokinetic analysis confirmed that cut finasteride tablets deliver bioequivalent drug exposure. [6] Some telehealth providers and dermatologists recommend this approach to reduce monthly costs to under $8.

Insurance Coverage Patterns

Most commercial insurance plans cover generic finasteride 5 mg for BPH under Tier 1 or Tier 2. Coverage for finasteride 1 mg for androgenetic alopecia is inconsistent because many insurers classify hair loss as cosmetic. Medicare Part D covers finasteride 5 mg for BPH but generally excludes 1 mg for hair loss under the cosmetic exclusion at 42 USC §1395y(a)(10). [7]

Patients whose insurer denies the 1 mg dose have three options: appeal the denial with documentation of medical necessity, ask their prescriber to write for 5 mg with instructions to split tablets, or use a discount card instead of insurance.

Patient Assistance Programs for Finasteride

Patient assistance programs (PAPs) are manufacturer-run or nonprofit-run programs that provide branded drugs at no cost or reduced cost to income-eligible patients. Generic drugs are not typically covered by manufacturer PAPs because manufacturers cannot recoup those costs. The framework below organizes the programs a clinician or patient should check, in order of likely cost reduction.

Merck Patient Assistance Program

Merck offers the Merck Patient Assistance Program for uninsured or underinsured patients who cannot afford Propecia or Proscar. Income eligibility generally requires a household income at or below 200 to 400% of the federal poverty level, though thresholds are updated annually. Applications are submitted at merckhelps.com (a separate site from Merck's main domain). [8] Approval provides a 90-day supply of brand Propecia or Proscar at no charge, renewable with annual re-enrollment.

Patients who qualify for Medicaid rarely qualify simultaneously for a Merck PAP, because Medicaid enrollment disqualifies most applicants. The program targets the coverage gap population, specifically those above Medicaid thresholds but without employer insurance.

NeedyMeds and RxAssist Databases

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain searchable databases of PAPs, including finasteride. These nonprofit aggregators list both manufacturer programs and state pharmaceutical assistance programs (SPAPs), which vary by state and are funded through Medicaid waiver money or state budgets. [9] Some SPAPs in states like Pennsylvania and New Jersey have covered finasteride for BPH in elderly patients with incomes above standard Medicaid limits.

Copay Assistance for Insured Patients

Merck's copay savings card for Propecia reduces out-of-pocket costs for commercially insured patients. As of 2025, eligible patients may pay as little as $20 per 30-day fill. The card does not work for Medicare or Medicaid beneficiaries under federal anti-kickback rules, specifically the Office of Inspector General's guidance on manufacturer copay assistance. [10]

Discount Cards, Coupons, and Cash-Pay Strategies

GoodRx, RxSaver, and Blink Health

GoodRx, RxSaver, and Blink Health negotiate pre-negotiated discounts with pharmacy benefit managers and pass the savings to cash-paying patients. These are not insurance. They are discount programs that override the pharmacy's retail price.

For generic finasteride 1 mg (30 tablets), GoodRx prices ranged from approximately $9 at Walmart to $22 at CVS in late 2025, depending on ZIP code. [5] Blink Health's model allows pre-payment online and locks in the price before the patient arrives at the pharmacy. Patients should compare all three platforms because prices vary by pharmacy and by month as contracts change.

Pharmacy membership programs, such as Amazon Pharmacy Prime discounts and Costco's internal pricing, often beat GoodRx for a 90-day supply. A 90-tablet supply of generic finasteride 1 mg cost approximately $18, $24 through Amazon Pharmacy with a Prime membership in 2025.

Telehealth Platforms and Bundled Pricing

Several telehealth platforms, including Hims, Keeps, and HealthRX, offer finasteride subscriptions that bundle the physician consultation, prescription, and pharmacy fulfillment into a single monthly fee. These range from $20 to $35 per month for finasteride 1 mg. The convenience trade-off is that patients pay a bundled rate rather than choosing the cheapest individual pharmacy. For patients who lack a primary care provider, the telehealth route may still be the most cost-efficient path when consultation costs are factored in. A 2021 cross-sectional study in JAMA Dermatology found that telehealth prescribing of finasteride increased access for men in rural counties where dermatologist density is below 1 per 100,000 population. [11]

90-Day Supplies vs. 30-Day Supplies

Dispensing fees are charged per fill, not per tablet. Requesting a 90-day supply rather than a 30-day supply eliminates two dispensing fees per quarter. At pharmacies charging $3, $5 per fill, that saves $6, $10 per quarter. Some insurers require a 90-day mail-order fill after the second fill of a maintenance medication, which can also reduce costs.

HSA and FSA Eligibility for Finasteride

Is Finasteride HSA/FSA Eligible?

Yes. Finasteride is an eligible medical expense for Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) when prescribed by a licensed clinician for a medical condition. The IRS defines eligible medical expenses under Section 213(d) of the Internal Revenue Code, which includes prescription drugs. [12] Because finasteride requires a prescription in the United States, it automatically qualifies for HSA and FSA reimbursement when a valid prescription exists.

Patients using finasteride for androgenetic alopecia should ensure their prescription is written for alopecia or hair loss, not for "cosmetic" purposes. An IRS private letter ruling clarified that treatments for a medically diagnosed condition, even one with cosmetic implications, qualify under Section 213(d) when a physician certifies the medical necessity. [13]

How to Pay with an HSA or FSA

Most HSA and FSA cards function as debit cards and can be swiped at the pharmacy point of sale. Patients who paid out of pocket can also submit receipts for reimbursement through their plan administrator. The receipt must show the drug name, quantity, date, and pharmacy. Online pharmacy receipts from Amazon Pharmacy, Hims, Keeps, or other telehealth platforms are accepted by most FSA/HSA administrators as long as the documentation includes a prescription number.

HSA funds roll over indefinitely. FSA funds typically expire December 31 or March 15 under a grace period election, or up to $640 may roll over under the carryover election (2024 IRS limit). Patients with unspent FSA funds near year-end should consider purchasing a 90-day supply of finasteride to avoid forfeiting funds. [14]

HSA Contribution Limits in 2025 and 2026

The IRS set the 2025 HSA contribution limit at $4,300 for self-only coverage and $8,550 for family coverage (Rev. Proc. 2024-25). The 2026 limits were announced at $4,400 and $8,750 respectively. [15] Patients with high-deductible health plans who are not yet contributing the maximum are leaving tax-advantaged dollars on the table that could directly offset finasteride costs.

Finasteride for Off-Label Populations: Access Considerations

Female-Pattern Hair Loss

The FDA has not approved finasteride for women, but the American Academy of Dermatology's 2023 hair loss guidelines note that finasteride 1 to 5 mg daily has Grade B evidence for female-pattern hair loss. [4] Women of childbearing potential face a contraindication due to teratogenicity risk in male fetuses, specifically the risk of hypospadias documented in the 1992 FDA label for Proscar. [16] Women who are postmenopausal or who use reliable contraception can be prescribed finasteride off-label. Access for this group follows the same cost pathways described above, with the additional step that some pharmacies require a pharmacist counseling note confirming the patient understands the pregnancy contraindication before dispensing.

Gender-Affirming Care

Finasteride is used in gender-affirming hormone therapy (GAHT) as an androgen blocker, primarily for transgender women or nonbinary individuals who want to reduce dihydrotestosterone (DHT) levels before or alongside estrogen. The Endocrine Society's 2017 clinical practice guideline on gender dysphoria recommends anti-androgen therapy and lists finasteride as an option. [17] Updated guidance from the World Professional Association for Transgender Health (WPATH) Standards of Care Version 8 (2022) similarly lists finasteride as an acceptable anti-androgen. [18]

Access for GAHT patients is complicated by inconsistent insurance coverage and, in some states, by age-related policy debates. In states where GAHT for minors has been restricted, finasteride prescribing for adolescents with gender dysphoria may be subject to additional legal review. Adult patients face the same cost field as other finasteride users. Informed consent models used by most telehealth GAHT platforms allow prescription after documented counseling, without requiring a formal mental health diagnosis, consistent with WPATH SOC-8 recommendations.

Adolescents With Early-Onset Androgenetic Alopecia

Androgenetic alopecia can present before age 18. Finasteride's FDA approval specifies use in men aged 18 and older. Prescribing it to adolescents is off-label. A small open-label study published in Pediatric Dermatology (N=36) followed adolescent males aged 14 to 17 for 24 months on finasteride 1 mg daily and reported a 74% rate of stabilization or improvement without serious adverse events. [19] Prescribers using finasteride in this population operate outside the label and should document informed consent with parents or guardians. No formal expanded access application to the FDA is required for this off-label use.

Understanding the Finasteride Evidence Base

Knowing that the drug is cheap is one thing. Knowing that the drug works is the reason to spend anything on it.

Key Trial Data for Androgenetic Alopecia

The original approval was supported by two phase III randomized controlled trials. In a combined analysis (N=1,553), finasteride 1 mg daily for 2 years increased hair count by a mean of 107 hairs per 1-inch-diameter circle vs. A loss of 138 hairs in the placebo group (P<0.001). [20] A 5-year open-label extension showed that 90% of men who continued treatment maintained or increased hair count compared with baseline. Discontinuation leads to reversal of benefit within 6 to 12 months, which means treatment is continuous rather than curative, directly relevant to long-term cost planning.

Benign Prostatic Hyperplasia Data

The PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040) demonstrated that finasteride 5 mg daily for 4 years reduced the risk of acute urinary retention by 57% and the risk of BPH-related surgery by 55% compared with placebo (P<0.001). [21] The American Urological Association's 2023 BPH guideline gives finasteride a strong recommendation for patients with prostate volume greater than 30 mL or PSA greater than 1.5 ng/mL. [22]

Sexual Side Effect Profile

The most discussed safety concern is post-finasteride syndrome, a contested condition characterized by persistent sexual, neurological, and psychological side effects after discontinuation. The FDA added a label update in 2012 requiring disclosure of persistent sexual adverse events. [23] In the PLESS trial, sexual dysfunction occurred in 15.8% of finasteride-treated men vs. 10.1% of placebo-treated men at year one, with rates converging by year four. A 2020 BMJ meta-analysis of 29 trials found a statistically significant increase in sexual dysfunction with finasteride (OR 1.63, 95% CI 1.42 to 1.87). [24] Patients and prescribers should discuss this risk before initiating therapy, and cost-planning conversations should include the realistic possibility of discontinuation.

Practical Step-by-Step: Lowest-Cost Path to Finasteride in 2026

The sequence below represents the lowest-cost approach for an adult male patient with androgenetic alopecia who has no insurance covering the 1 mg dose.

1. Get a prescription from a primary care physician, dermatologist, or telehealth platform. Telehealth consultations for finasteride often cost $0, $25 as a first-visit promotional rate.
2. Ask the prescriber to write for generic finasteride 1 mg, 90-tablet supply, with one refill.
3. Compare GoodRx, RxSaver, and Blink Health prices at pharmacies within your ZIP code or accessible by mail.
4. Check Amazon Pharmacy if you have Amazon Prime. Compare the Prime member price for a 90-tablet supply.
5. If your household income is below 400% of the federal poverty level and you need brand Propecia, apply to the Merck Patient Assistance Program at merckhelps.com.
6. Pay with your HSA or FSA card to effectively reduce the after-tax cost by your marginal tax rate (typically 22 to 32% for most working adults). [12]
7. If cost still exceeds $15 per month after steps 1 to 6, ask your prescriber to write for finasteride 5 mg with instructions to split tablets into quarters, yielding approximately 1.25 mg per dose at roughly one-quarter the price per milligram. [6]